EUCTR2013-005536-17-ES进行中(未招募)1 期
Multicenter, randomized and double-blinded clinical trial on the use of antibiotic prophylaxis for EUS guided FNA of pancreatic cystic lesions
Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau ? IIB Sant Pau0 个研究点目标入组 218 人开始时间: 2014年6月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 218
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients with a pancreatic cyst requiring EUS-FNA to complete evaluation.
- •- Participant is willing and able to give informed consent for participation in the study.
- •- Age 18 years or older.
- •- Ability to understand study procedures and to comply with them for the entire length of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 218
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Patients with other co-morbidities requiring antibiotic prophylaxis for endoscopic invasive procedures (such as those with cardiac valve prosthesis).
- •- Cystic lesion of the intestinal wall (foregut or duplication cyst).
- •- Use of antibiotic treatment for any other indication during the 5 days prior to the procedure.
- •- Pregnant woman.
- •- Known allergy/sensitivity to ciprofloxacin.
- •- Inability or unwillingness of individual or legal guardian/representative to give written informed consent.
研究者
相似试验
进行中(未招募)
1 期
Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal insufficiency in predialysis patientsEUCTR2007-001906-26-FRHEXAL Biotech ForschungsGmbH300
进行中(未招募)
不适用
Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal insufficiency in predialysis patientsEUCTR2007-001906-26-ATHEXAL AG300
进行中(未招募)
不适用
Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal insufficiency in predialysis patientsEUCTR2007-001906-26-BGHEXAL Biotech ForschungsGmbH300
进行中(未招募)
1 期
Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal insufficiency in predialysis patientsanemia associated with chronic renal insufficiency in predialysis patientsMedDRA version: 9.1Level: LLTClassification code 10058116Term: Nephrogenic anaemiaEUCTR2007-001906-26-SKHEXAL Biotech ForschungsGmbH300
进行中(未招募)
不适用
Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal insufficiency in predialysis patientsanemia associated with chronic renal insufficiency in predialysis patientsMedDRA version: 9.1Level: LLTClassification code 10058116Term: Nephrogenic anaemiaEUCTR2007-001906-26-DEHEXAL AG300
